ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 157 filers reported holding ASCENDIS PHARMA A/S in Q2 2020. The put-call ratio across all filers is 0.39 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $3,568 | -99.7% | 29,218 | +123.0% | 0.01% | +150.0% |
| Q2 2022 | $1,218,000 | +413.9% | 13,105 | +548.8% | 0.00% | – |
| Q1 2022 | $237,000 | -39.8% | 2,020 | -42.3% | 0.00% | -100.0% |
| Q1 2020 | $394,000 | -70.2% | 3,500 | -74.5% | 0.00% | -66.7% |
| Q3 2019 | $1,320,000 | -18.3% | 13,700 | -46.9% | 0.00% | -25.0% |
| Q4 2018 | $1,616,000 | +12.2% | 25,799 | +27.0% | 0.00% | +33.3% |
| Q3 2018 | $1,440,000 | -25.2% | 20,315 | -29.8% | 0.00% | -40.0% |
| Q2 2018 | $1,926,000 | – | 28,952 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |